Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adoptive cellular therapies: the current landscape
Maartje W. Rohaan, Sofie Wilgenhof, John B.A.G. Haanen
Virchows Archiv (2018) Vol. 474, Iss. 4, pp. 449-461
Open Access | Times Cited: 346

Showing 1-25 of 346 citing articles:

Therapeutic Targeting of the Tumor Microenvironment
Leire Bejarano, Marta Joana Costa Jordão, Johanna A. Joyce
Cancer Discovery (2021) Vol. 11, Iss. 4, pp. 933-959
Open Access | Times Cited: 1062
Tumor-infiltrating lymphocytes in the immunotherapy era
Sterre T. Paijens, Annegé Vledder, Marco de Bruyn, et al.
Cellular and Molecular Immunology (2020) Vol. 18, Iss. 4, pp. 842-859
Open Access | Times Cited: 640
Neoantigens: promising targets for cancer therapy
Na Xie, Guobo Shen, Wei Gao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 460
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Andrew M. K. Law, Fátima Valdés‐Mora, David Gallego‐Ortega
Cells (2020) Vol. 9, Iss. 3, pp. 561-561
Open Access | Times Cited: 379
Cervical Cancer Immunotherapy: Facts and Hopes
Louise Ferrall, Ken Y. Lin, Richard B.S. Roden, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 18, pp. 4953-4973
Open Access | Times Cited: 257
Signal pathways of melanoma and targeted therapy
Weinan Guo, Huina Wang, Chunying Li
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 224
Promises and challenges of adoptive T-cell therapies for solid tumours
Matteo Morotti, Ashwag Albukhari, Abdulkhaliq Alsaadi, et al.
British Journal of Cancer (2021) Vol. 124, Iss. 11, pp. 1759-1776
Open Access | Times Cited: 200
Cell Therapy: Types, Regulation, and Clinical Benefits
Abed El-Hakim El-Kadiry, Moutih Rafei, Riam Shammaa
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 159
Cancer immunotherapy: Challenges and limitations
Sina Taefehshokr, Aram Parhizkar, Shima Hayati, et al.
Pathology - Research and Practice (2021) Vol. 229, pp. 153723-153723
Closed Access | Times Cited: 108
CAR-NK Cells in the Treatment of Solid Tumors
Ewa Wrona, Maciej Borowiec, Piotr Potemski
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 5899-5899
Open Access | Times Cited: 106
Current updates on generations, approvals, and clinical trials of CAR T-cell therapy
Tadesse Asmamaw Dejenie, Markeshaw Tiruneh G Medhin, Gashaw Dessie Terefe, et al.
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 6
Open Access | Times Cited: 94
Gold Nanoparticles: Construction for Drug Delivery and Application in Cancer Immunotherapy
Huiqun Huang, Ronghui Liu, Jie Yang, et al.
Pharmaceutics (2023) Vol. 15, Iss. 7, pp. 1868-1868
Open Access | Times Cited: 78
Tumor microenvironment and immunotherapy of oral cancer
Chang Liu, Min Wang, Haiyang Zhang, et al.
European journal of medical research (2022) Vol. 27, Iss. 1
Open Access | Times Cited: 75
CAR T Cell Therapy: A Versatile Living Drug
Rodrigo C. De Marco, Héctor J. Monzó, Päivi M. Ojala
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6300-6300
Open Access | Times Cited: 63
Adoptive cell therapy for cancer treatment
Shi Du, Jinyue Yan, Yonger Xue, et al.
Exploration (2023) Vol. 3, Iss. 4
Open Access | Times Cited: 44
Biomaterials for in situ cell therapy
Chang Wang, Siyu Wang, Diana D. Kang, et al.
BMEMat (2023) Vol. 1, Iss. 3
Open Access | Times Cited: 41
The quest for nanoparticle-powered vaccines in cancer immunotherapy
Zhe Sun, Hui Zhao, Li Ma, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 24
Cancer Nanovaccines: Nanomaterials and Clinical Perspectives
Nimeet Desai, Vivek P. Chavda, Thakur Raghu Raj Singh, et al.
Small (2024) Vol. 20, Iss. 35
Open Access | Times Cited: 24
Engineered Bio‐Based Hydrogels for Cancer Immunotherapy
Yuxuan Peng, Shuang Liang, Qian‐Fang Meng, et al.
Advanced Materials (2024) Vol. 36, Iss. 21
Closed Access | Times Cited: 21
CD8+ T cell-based cancer immunotherapy
Yanxia Chen, Dingning Yu, Hui Qian, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 19
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition
Antonino Glaviano, Hannah Lau, Lukas M. Carter, et al.
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access | Times Cited: 10
Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach
Miguel López de Rodas, María Villalba, Miguel F. Sanmamed, et al.
Nature Reviews Clinical Oncology (2025)
Closed Access | Times Cited: 5
Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer
Amrendra Kumar, Reese Watkins, Anna E. Vilgelm
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 94
Ten‐year update of the international registry on cytokine‐induced killer cells in cancer immunotherapy
Ying Zhang, Ingo G.H. Schmidt‐Wolf
Journal of Cellular Physiology (2020) Vol. 235, Iss. 12, pp. 9291-9303
Open Access | Times Cited: 81
Immune cells as tumor drug delivery vehicles
Francis Combes, Evelyne Meyer, Niek N. Sanders
Journal of Controlled Release (2020) Vol. 327, pp. 70-87
Open Access | Times Cited: 78
Page 1 - Next Page

Scroll to top